SEC Comment Letter for VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Jul 6, 2012
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: July 6, 2012 · CIK: 0000093314 · Accession: 0000000000-12-035195
AI Filing Summary & Sentiment
Reasoning
Letter
July 5, 2012 Via Email Cameron Reynolds President and Chief Executive Officer VolitionRX Limited 150 Orchard Road Orchard Plaza 08 -02 Singapore 238841
Re: VolitionRX Limited Form 8-K Filed October 13, 2011 File No. 000 -30402 Form 10 -K for Fiscal Year Ended August 31, 2010 Filed November 4, 2010 Form 10 -K for Fiscal Year Ended August 31, 2011 Filed November 29, 2011 Form 10 -KT for Fiscal Year Ended December 31, 2011 Filed April 16, 2012
Dear Mr. Reynolds :
We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ James Lopez (for)
Show Raw Text
July 5, 2012 Via Email Cameron Reynolds President and Chief Executive Officer VolitionRX Limited 150 Orchard Road Orchard Plaza 08 -02 Singapore 238841 Re: VolitionRX Limited Form 8-K Filed October 13, 2011 File No. 000 -30402 Form 10 -K for Fiscal Year Ended August 31, 2010 Filed November 4, 2010 Form 10 -K for Fiscal Year Ended August 31, 2011 Filed November 29, 2011 Form 10 -KT for Fiscal Year Ended December 31, 2011 Filed April 16, 2012 Dear Mr. Reynolds : We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ James Lopez (for) John Reynolds Assistant Director